Effect of prenatal dexamethasone on immunoreactive 6-ketoprostaglandin F levels in fetal rat lungs

Michael Y Tsai, Bill Handschin, Bradley J. Syverson, Mark W. Josephson, David M. Brown

Research output: Contribution to journalArticlepeer-review

4 Scopus citations

Abstract

The effect of prenatal glucocorticoid treatment on levels of immunoreactive 6-ketoprostaglandin F,1α(PGF) (the stable metabolite of prostacyclin) was studied in fetal rat lungs. During late gestation (20-22 days), levels of 6-keto-PGF peaked at 21 days in offspring of control mothers. At a maternal dose of 0.2 mg/kg dexamethasone, maximal enhancement of fetal 6-keto-PGF levels occurred at 20 days gestation. At a treatment dose of 0.4 mg/kg, however, dexamethasone increased fetal lung 6-keto-PGF concentrations throughout late gestation. Because maturation of fetal lung is known to be delayed in males relative to females, we also studied the impact of sex of the fetus on levels of 6-keto-PGF. Our results showed no statistically significant differences between females and males in any of the treatment groups at an of the gestational ages studied. These results suggest that prenatal dexamethasone enhances endogenous levels of 6-keto-PGF in fetal rat lungs. Since prostacyclin may play important roles in fetal lung maturation and neonatal lung function, the effectiveness of prenatal glucocorticoid therapy for accelerating functional maturity of the fetal lung may in part be due to stimulation of prostacyclin synthesis.

Original languageEnglish (US)
Pages (from-to)908-911
Number of pages4
JournalPediatric Research
Volume18
Issue number9
DOIs
StatePublished - Sep 1984

Fingerprint Dive into the research topics of 'Effect of prenatal dexamethasone on immunoreactive 6-ketoprostaglandin F<sub>1α</sub> levels in fetal rat lungs'. Together they form a unique fingerprint.

Cite this